Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
Am. J. Ophthalmol., Jun;143(6):958-969 (2007)
Erythropoiesis-stimulating agents in oncology.
J Natl Compr Canc Netw., Jul;6(6):565-75 (2008)
Erythropoietin in cancer patients.
Annu. Rev. Med., 60:181-92 (2009)
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
Clin. Cancer Res., Jan;15(1):390-9 (2009)
Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
Cancer., Mar;115(5):1121-31 (2009)
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
Clin. Cancer Res., Oct;15(19):6267-76 (2009)
Do we need a different set of response assessment criteria for tumor immunotherapy?
Clin. Cancer Res., Dec;15(23):7116-8 (2009)
Randomized controlled trials of the erythroid-stimulating agents in cancer patients.
Cancer Treat. Res., 157:195-215 (2011)
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Clin. Cancer Res., Jun;17(12):4101-9 (2011)
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Cancer., Mar;97(5):1312-20 (2003)
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.
Clin. Cancer Res., Mar;9(3):998-1008 (2003)
Current developments in cancer vaccines and cellular immunotherapy.
J. Clin. Oncol., Jun;21(12):2415-32 (2003)
Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
J. Immunol., Apr;172(8):4762-9 (2004)
Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
Control Clin Trials., Aug;25(4):400-7 (2004)
Entering a new era in the management of tumor-associated involution.
J Support Oncol., 3(1):51-2 (2005)
Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Cancer Gene Ther., Jun;12(6):516-27 (2005)
The development of erythropoietic agents in oncology.
Expert Opin Emerg Drugs., Aug;10(3):553-67 (2005)
Novel interactions of vitamin E and estrogen in breast cancer.
Nutr Cancer., 52(1):43-8 (2005)
Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice.
Cancer Immunol. Immunother., Jun;55(6):663-71 (2006)
Cancer patient survival and erythropoietin.
J Natl Compr Canc Netw., Nov;3(6):796-804 (2005)